Passage Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Passage Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Passage Bio Inc PASG.OQ reported a quarterly adjusted loss of $2.44 per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-2.96. The mean expectation of three analysts for the quarter was for a loss of $2.65 per share. Wall Street expected results to range from $-3.47 to $-2.20 per share.
Reported revenue was zero; analysts expected zero.
Passage Bio Inc's reported EPS for the quarter was a loss of $2.44.
The company reported a quarterly loss of $7.82 million.
Passage Bio Inc shares had fallen by 9.8% this quarter and lost 62.7% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 14.3% in the last three months.
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Passage Bio Inc is $15.50, about 71.6% above its last closing price of $4.40
This summary was machine generated from LSEG data August 10 at 01:31 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -2.65 | -2.44 | Beat |
Mar. 31 2026 | -2.79 | -2.16 | Beat |
Dec. 31 2025 | -2.57 | -3.95 | Missed |
Sep. 30 2025 | -2.80 | -2.44 | Beat |